Last Updated : June 18, 2020
Details
FilesGeneric Name:
fluticasone furoate/vilanterol
Project Status:
Withdrawn
Therapeutic Area:
COPD
Manufacturer:
GlaxoSmithKline Inc.
Call for patient/clinician input open:
Brand Name:
Breo Ellipta
Project Line:
Reimbursement Review
Project Number:
SR0524-000
Call for patient/clinician input closed:
Biosimilar:
No
Submission Type:
Resubmission
Indications:
COPD
Date NOC Issued:
Key Milestones2 | |
---|---|
Call for patient input posted | May 31, 2017 |
Patient group input closed | July 20, 2017 |
Clarification: - Patient input submission received | |
Patient input summary sent for review to patient input groups | July 25, 2017 |
Patient group comments on input summary closed | August 01, 2017 |
Clarification: - Patient input summary feedback received | |
Submission received | June 28, 2017 |
Submission accepted | July 13, 2017 |
Review initiated | July 14, 2017 |
Draft CADTH review report(s) sent to sponsor | September 28, 2017 |
Comments from sponsor on draft CADTH review report(s) received | October 10, 2017 |
Redaction requests from sponsor on draft CADTH review report(s) received | October 17, 2017 |
CADTH review team's comments on draft CADTH review report(s) sent to sponsor | November 03, 2017 |
Clarification: - Voluntarily withdrawn by the manufacturer on 2017-Nov-09 |
Files
Last Updated : June 18, 2020